BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26168498)

  • 1. Improvement of Impaired Immunological Status of Patients with Various Types of Advanced Cancers by Autologous Immune Cell Therapy.
    Kamigaki T; Ibe H; Okada S; Matsuda E; Tanaka M; Oguma E; Kinoshita Y; Ogasawara S; Ono A; Makita K; Naitoh K; Goto S
    Anticancer Res; 2015 Aug; 35(8):4535-43. PubMed ID: 26168498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy.
    Noguchi A; Kaneko T; Naitoh K; Saito M; Iwai K; Maekawa R; Kamigaki T; Goto S
    Int Immunopharmacol; 2014 Jan; 18(1):90-7. PubMed ID: 24269583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
    Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
    Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of safety of immune-cell therapy for patients with various types of advanced cancer.
    Kamigaki T; Matsuda E; Okada S; Naitoh K; Kondo T; Ibe H; Maekawa R; Goto S
    Anticancer Res; 2014 Aug; 34(8):4601-7. PubMed ID: 25075106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future applications of cellular therapies for cancer.
    Copier J; Bodman-Smith M; Dalgleish A
    Immunotherapy; 2011 Apr; 3(4):507-16. PubMed ID: 21463192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
    Liu M; Xie J; Zhao S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
    Wada J; Yamasaki A; Nagai S; Yanai K; Fuchino K; Kameda C; Tanaka H; Koga K; Nakashima H; Nakamura M; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2008; 28(4C):2401-8. PubMed ID: 18751426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer.
    Skachkova OV; Khranovska NM; Gorbach OI; Svergun NM; Sydor RI; Nikulina VV
    Exp Oncol; 2013 Jun; 35(2):109-13. PubMed ID: 23828386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells.
    Cui F; Ji J; Lv H; Qu D; Yu C; Yang Y; Xu Y
    J Cancer Res Ther; 2013 Nov; 9 Suppl():S162-8. PubMed ID: 24516054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
    López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
    Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
    Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
    Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Whiteside TL; Furuya N
    Head Neck; 2007 Feb; 29(2):120-7. PubMed ID: 17103408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.
    Hus I; Schmitt M; Tabarkiewicz J; Radej S; Wojas K; Bojarska-Junak A; Schmitt A; Giannopoulos K; Dmoszyńska A; Roliński J
    Leukemia; 2008 May; 22(5):1007-17. PubMed ID: 18323802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionally distinct subsets of CD4⁺ regulatory T cells in patients with laryngeal squamous cell carcinoma are indicative of immune deregulation and disease progression.
    Sun W; Li WJ; Fu QL; Wu CY; Lin JZ; Zhu XL; Hou WJ; Wei Y; Wen YH; Wang YJ; Wen WP
    Oncol Rep; 2015 Jan; 33(1):354-62. PubMed ID: 25333227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.